vs
Side-by-side financial comparison of FrontView REIT, Inc. (FVR) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $16.5M, roughly 1.2× FrontView REIT, Inc.). FrontView REIT, Inc. runs the higher net margin — -24.9% vs -90.7%, a 65.8% gap on every dollar of revenue.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
FVR vs NAMS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.5M | $19.1M |
| Net Profit | $-4.1M | $-17.4M |
| Gross Margin | — | — |
| Operating Margin | — | -186.1% |
| Net Margin | -24.9% | -90.7% |
| Revenue YoY | — | 740.1% |
| Net Profit YoY | — | 55.5% |
| EPS (diluted) | $-0.19 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.5M | — | ||
| Q3 25 | $16.8M | — | ||
| Q2 25 | $17.6M | $19.1M | ||
| Q1 25 | $16.2M | — | ||
| Q4 24 | — | $12.8M | ||
| Q3 24 | $14.5M | $29.1M | ||
| Q2 23 | — | $8.6M |
| Q4 25 | $-4.1M | — | ||
| Q3 25 | $4.0M | — | ||
| Q2 25 | $-2.9M | $-17.4M | ||
| Q1 25 | $-833.0K | — | ||
| Q4 24 | — | $-92.2M | ||
| Q3 24 | $-2.4M | $-16.6M | ||
| Q2 23 | — | $-42.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -186.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -338.5% | ||
| Q3 24 | — | -85.9% | ||
| Q2 23 | — | -461.8% |
| Q4 25 | -24.9% | — | ||
| Q3 25 | 23.9% | — | ||
| Q2 25 | -16.5% | -90.7% | ||
| Q1 25 | -5.1% | — | ||
| Q4 24 | — | -721.7% | ||
| Q3 24 | -16.7% | -57.2% | ||
| Q2 23 | — | -486.9% |
| Q4 25 | $-0.19 | — | ||
| Q3 25 | $0.19 | — | ||
| Q2 25 | $-0.16 | $-0.15 | ||
| Q1 25 | $-0.06 | — | ||
| Q4 24 | — | $-0.91 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 23 | — | $-0.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.5M | $739.2M |
| Total DebtLower is stronger | $314.3M | — |
| Stockholders' EquityBook value | $391.2M | $778.5M |
| Total Assets | $854.4M | $815.1M |
| Debt / EquityLower = less leverage | 0.80× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.5M | — | ||
| Q3 25 | $19.6M | — | ||
| Q2 25 | $8.4M | $739.2M | ||
| Q1 25 | $3.3M | — | ||
| Q4 24 | — | $834.2M | ||
| Q3 24 | — | $422.7M | ||
| Q2 23 | — | — |
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | — | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | $391.2M | — | ||
| Q3 25 | $385.2M | — | ||
| Q2 25 | $369.9M | $778.5M | ||
| Q1 25 | $324.7M | — | ||
| Q4 24 | — | $757.5M | ||
| Q3 24 | $1.0K | $378.9M | ||
| Q2 23 | — | $398.4M |
| Q4 25 | $854.4M | — | ||
| Q3 25 | $846.8M | — | ||
| Q2 25 | $856.5M | $815.1M | ||
| Q1 25 | $860.8M | — | ||
| Q4 24 | — | $864.6M | ||
| Q3 24 | $1.0K | $439.2M | ||
| Q2 23 | — | — |
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $42.1M | $-37.7M |
| Free Cash FlowOCF − Capex | — | $-37.8M |
| FCF MarginFCF / Revenue | — | -197.2% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $42.1M | — | ||
| Q3 25 | $8.3M | — | ||
| Q2 25 | $9.3M | $-37.7M | ||
| Q1 25 | $8.1M | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.5M | ||
| Q2 23 | — | $-31.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-37.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.6M | ||
| Q2 23 | — | $-31.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -197.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -293.5% | ||
| Q3 24 | — | -43.2% | ||
| Q2 23 | — | -369.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 23 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
